June 19, 2024
2 min watch
Save
VIDEO: Oral treatment shows promise in slowing diabetic retinopathy progression
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jay S. Pepose, MD, PhD, of Ocuphire Pharma, discusses an oral small-molecule Ref-1 inhibitor for nonproliferative diabetic retinopathy.
According to Pepose, the treatment slowed diabetic retinopathy progression in a phase 2 study and will soon enter a new clinical trial.
“If we can slow the progression of diabetic retinopathy that is associated with vision-threatening complications, this would be a huge paradigm shift for our patients,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Pepose reports being the chief medical advisor for Ocuphire Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.